|
Books > Medicine > Other branches of medicine > Pharmacology
|
Buy Now
Advances in Antiviral Drug Design, Volume 4 (Hardcover, 5 Ed)
Loot Price: R2,980
Discovery Miles 29 800
|
|
|
Advances in Antiviral Drug Design, Volume 4 (Hardcover, 5 Ed)
Series: Advances in Antiviral Drug Design
Expected to ship within 12 - 17 working days
|
The fourth volume of "Advances in Antiviral Drug Design" is keeping
up with the recent progress made in the broad field of antiviral
drug research and encompasses six specific directions that have
opened new avenues for the treatment of HIV and other virus
infections.
First, as the introductory chapter, the different new anti-HIV
agents that are now in preclinical or clinical development are
reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs,
but also HIV entry/fusion inhibitors as well as integrase
inhibitors, and some of these agents, such as the NRTI
emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed
for clinical use.
Second, high expectations are vested in the potential therapeutic
usefulness of inhibitors of HIV integration, a point of no return
in the life cycle of HIV, and this approach is highlighted by D.J.
Hazuda and S.D. Young.
Third, as all currently available PIs can be described as
"peptidomimetic," and, therefore, expected to demonstrate
overlapping virus-drug resistance and side effect profiles, it
would be interesting to see how a non-peptidic protease inhibitor
such as tipranavir behaves, and this is covered by D. Mayers, K.
Curry, V. Kohlbrenner and S. McCallister.
Fourth, neuraminidase inhibitors such as zanamivir (that has to be
inhaled) and oseltamivir (that can be administered via the oral
route) have gained a definitive status as antiviral drugs useful
for both therapy and prophylaxis of influenza A and B virus
infections; as they target a specific influenza viral enzyme,
neuraminidase (or sialidase), they may be expected to block newly
emerging influenza viruses as well, and the design of neuraminidase
inhibitorshas received due attention of H. Jin and C.U. Kim.
Fifth, while the major current efforts in antiviral drug
development have shifted from herpesviruses towards HIV and
hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus
(HCV)], it is interesting to note that by switching from the
classical five-membered sugar or acyclic nucleoside strategy, J.
Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing
six-membered carbocyclic nucleosides as potential anti-herpesvirus
agents.
Sixth, following up on the nucleotide prodrug strategy introduced
above under ix, to deliver the biologically active nucleotides
inside the cells, C. Meier has elaborated on a particular class of
such pronucleotides, namely that of the cyclosaligenyl
pronucleotides, an approach that should have far reaching
implications for compounds effective against HIV, HBV and other
viruses.
The six topics covered in this fourth volume of "Advances in
Antiviral Drug Design" are in the front line of the present
endeavors towards the design and development of new therapeutic
agents for virus infections. They pertain to the combat against
three of the most important viral pathogens of current times: HIV,
HBV, influenza virus and herpesviruses.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
